Objectif Cell-based therapy (CBT) for cure of difficult-to-treat cancer types is the most disruptive innovation in personalized medicine. However, patient-specific production of therapeutic immune cells is expensive and associated with remaining risks. In particular, it is known that only actively migrating immune cells are efficient against tumours cells, while inactive therapeutic cells can elicit adverse effects. Yet, there is no quality control (QC) regarding motility of therapeutic cells before patient treatment. The goal of the proposal is to promote an integrated bench-top instrument for reliable assessment of motility parameters in standardized cell culture carriers, i.e. the TimeLapseReader.As leading provider of live cell migration assays ibidi strives to market a complete QC solution based on an automated instrument in combination with ready-to-use QC kits, slides and reagents. The TimeLapseReader will allow robust and reproducible migration tests in manufacturing facilities and set a new standard for QC of immune cell in CBT.In Phase 1 the feasibility study will explore key parameters for QC in the most relevant therapeutic cell types and the best market entry strategy. Objectives include:• Identification of relevant QC parameters for therapeutic cells.• Setting up the business plan including competitor and freedom-to-operate analysis.• Strategy to obtain regulatory approval / CE-Marking for the final device version.Expected impact is eminent as CBT is going to enter the medical market with serval hundred to thousands of patients treated worldwide per year. It is expected, that up to 20% of all cancer patients can be cured with CTB within 10-15 years assuming serval millions QC per year. ibidi will apply for funding to validate QC tests in a Phase 2 proposal. Phase 2 will consolidate the technology and transform ibidi into a global player of medical QC in the CBT field. Champ scientifique medical and health sciencesmedical biotechnologycells technologiesstem cellsmedical and health sciencesbasic medicineimmunologyautoimmune diseasesmedical and health sciencesclinical medicineoncologymedical and health scienceshealth sciencespersonalized medicine Programme(s) H2020-EU.3.1. - SOCIETAL CHALLENGES - Health, demographic change and well-being Main Programme H2020-EU.3.1.3. - Treating and managing disease Thème(s) SMEInst-05-2016-2017 - Supporting innovative SMEs in the healthcare biotechnology sector Appel à propositions H2020-SMEInst-2016-2017 Voir d’autres projets de cet appel Sous appel H2020-SMEINST-1-2016-2017 Régime de financement SME-1 - SME instrument phase 1 Coordinateur IBIDI GMBH Contribution nette de l'UE € 50 000,00 Adresse AM KLOPFERSPITZ 19 82152 Planegg Martinsried Allemagne Voir sur la carte PME L’entreprise s’est définie comme une PME (petite et moyenne entreprise) au moment de la signature de la convention de subvention. Oui Région Bayern Oberbayern München, Landkreis Type d’activité Private for-profit entities (excluding Higher or Secondary Education Establishments) Liens Contacter l’organisation Opens in new window Site web Opens in new window Participation aux programmes de R&I de l'UE Opens in new window Réseau de collaboration HORIZON Opens in new window Coût total € 71 429,00
